427 related articles for article (PubMed ID: 33486302)
1. Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis.
Cassinello J; Domínguez-Lubillo T; Gómez-Barrera M; Hernando T; Parra R; Asensio I; Casado MA; Moreno P
Cancer Treat Rev; 2021 Feb; 93():102152. PubMed ID: 33486302
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?
Pereira-Salgado A; Kwan EM; Tran B; Gibbs P; De Bono J; IJzerman M
Eur Urol Focus; 2021 Jul; 7(4):752-763. PubMed ID: 32273196
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.
Zhang W; Wu TY; Chen Q; Shi XL; Xiao GA; Zhao L; Xu CL; Zhou T; Sun YH
Asian J Androl; 2017; 19(2):196-202. PubMed ID: 27212123
[TBL] [Abstract][Full Text] [Related]
6. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
7. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Urol Oncol; 2017 Jun; 35(6):432-437. PubMed ID: 28188090
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813
[TBL] [Abstract][Full Text] [Related]
9. Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Tsujino T; Tokushige S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Ohno T; Nakamori K; Maenosono R; Nishimura K; Yamazaki S; Uchimoto T; Yanagisawa T; Mori K; Urabe F; Tsuzuki S; Iwatani K; Yamamoto S; Takahara K; Inamoto T; Kimura T; Ohno Y; Shiroki R; Azuma H
Cancer Med; 2023 Oct; 12(19):19414-19422. PubMed ID: 37706578
[TBL] [Abstract][Full Text] [Related]
10. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Aug; 15(4):e591-e597. PubMed ID: 28063845
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA
Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961
[TBL] [Abstract][Full Text] [Related]
12. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
[TBL] [Abstract][Full Text] [Related]
13. Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer.
Freedland SJ; Li S; Pilon D; Bhak RH; Narkhede S; Lefebvre P; Young-Xu Y
Curr Med Res Opin; 2021 Apr; 37(4):635-642. PubMed ID: 33571020
[TBL] [Abstract][Full Text] [Related]
14. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
[TBL] [Abstract][Full Text] [Related]
16. Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience.
Fiala O; Hosek P; Korunkova H; Hora M; Kolar J; Windrichova J; Sorejs O; Topolcan O; Travnicek I; Sedlackova H; Finek J
Anticancer Res; 2023 Jan; 43(1):463-471. PubMed ID: 36585174
[TBL] [Abstract][Full Text] [Related]
17. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT).
Ternov KK; Sønksen J; Fode M; Lindberg H; Kistorp C; Bisbjerg R; Faber J; Klausen TW; Palapattu G; Østergren PB
Eur J Cancer; 2022 Aug; 171():75-84. PubMed ID: 35709600
[TBL] [Abstract][Full Text] [Related]
18. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.
Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Med Oncol; 2017 Nov; 34(12):200. PubMed ID: 29164346
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Moussa M; Papatsoris A; Abou Chakra M; Sryropoulou D; Dellis A
Expert Opin Pharmacother; 2020 Aug; 21(12):1431-1448. PubMed ID: 32469248
[TBL] [Abstract][Full Text] [Related]
20. Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
Clin Genitourin Cancer; 2015 Jun; 13(3):193-8. PubMed ID: 25466676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
